Month: May 2020

Published January 28, 2020 Investment sentiment is on the rise in the wake of confirmation that MedMen is attempting to pay vendors with equity – leading to further unknown dilution, the potential for a vicious circle and multiple compression as equity holders worry about cash flow. We have assumed an extra 14 million shares for MedMen assuming the company pays 10% of its $55 million in accounts payable using equity at the current price of $0.39 Read More

Published January 29, 2020 | By Mike Regan U.S. cannabis markets are a varied bunch. Sales growth at 10% in one market might be solid, but in another it could signal decline. Our partnership with Headset gives us access to estimates of sales data broken down by state (California, Colorado, Nevada and Washington) and product, and that information provides a baseline for investors looking to understand trends in each market. We have transformed the data to Read More

Published January 31, 2020 | By Mike Regan (Editor’s note: This article has been updated to clarify the compensation Bierman will receive for his shares.) Adam Biermen and super voting shares are no longer in charge at MedMen, which means the dilution of common shares might finally stop. But it remains to be seen if a new CEO can stop the bleeding and turn the business to create value for existing equity holders. Though he Read More

Published January 31, 2020 | By Craig Behnke and Mike Regan Adam Biermen steps down as CEO of MedMen  Adam Biermen and super voting shares are no longer in charge at MedMen (CSE: MMEN), which means the dilution of common shares might finally stop. But it remains to be seen if a new CEO can stop the bleeding and turn the business to create value for existing equity holders. Despite stepping down as CEO, Bierman will Read More